Former Republican Governor Rick Perry is backing legislation tabled by State Rep. Alex Dominguez, which pushes for psychedelic therapy treatments for veterans living with PTSD. The bill calls for a clinical study on psilocybin, which is the active ingredient found in magic mushrooms, to be conducted.
In an interview last week, Perry stated that the measure was an optimistic piece of legislation that legislators have the opportunity to discuss during this session.
Various studies have proposed that psilocybin could be an effective and safe treatment for various mental health conditions, such as depression. Perry noted that while he’s known to be very anti-drugs and still opposes the legalization of drugs for recreational use, he has observed how much psychedelic drugs can offer relief to veterans who have exhausted available treatment options and are going to other countries to seek alternative treatments.
The legislation, House Bill 1802, will direct the Health and Human Services Commission to carry out a clinical study on psilocybin, in collaboration with a Veterans Affairs hospital and a health sciences university.
Additionally, it asks that the state’s Health and Human Services Commission (“HHSC”) conduct a survey of previous studies that focus not only on psilocybin but also the use of ketamine and MDMA as a treatment for post-traumatic stress disorder. The HHSC will have to present quarterly reports on its study. The deadline has been set on December 1, 2024, and the HHSC will be required to submit ITS final findings to the members of both chambers, as well as the House speaker, lieutenant governor and the governor.
The legislation was advanced to the House Public Health Committee in March but is yet to receive a hearing.
In the recent past, we have seen many states legalizing cannabis for medicinal and recreational use, with some legalizing the use of psychedelics as well. However, the state of Texas has yet to do so. Instead, it has legalized cannabis with limited THC levels only for individuals suffering from debilitating illnesses being eligible to use it.
In an interview, Dominguez stated that colleagues from both sides of the aisle had been supportive of learning more about this substance. He explained that a majority of members wanted the study to be conducted and added that it would undergo a controlled process, with various safeguards set up to ensure that no individual would abuse the procedure, so that they could learn the drug’s effectiveness.
He revealed that his interest in the matter came from his time working as a Cameron County prosecutor, which established a treatment court for veterans in 2014.
The campaign to reform psychedelics laws in different jurisdictions will be helped a great deal by the scientific studies and medicine development efforts of numerous sector players such as XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) as its findings become public.
NOTE TO INVESTORS: The latest news and updates relating to XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) are available in the company’s newsroom at https://ibn.fm/XPHYF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.